Lorlatinib (Lorbrena) was superior to crizotinib (Xalkori) as an initial treatment for advanced ALK-positive non-small cell lung cancer, trial results show.
Bloggers, Unite! - bloggersunite.netBloggers, Unite! - bloggersunite.net - The News and Times Blog - AI News Briefs - Audio Posts